Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 6/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14610980 | 0.89 | FFAR1 (0.52) | NOS1SLC7A5CYP3A4FFAR1KDM4E | |
| SCHEMBL18500970 | 0.84 | SLC7A5 (0.42) | NOS1SLC7A5CYP3A4TSHR | |
| SCHEMBL23643105 | 0.83 | SLC7A5 (0.52) | NOS1SLC7A5 | |
| SCHEMBL23643229 | 0.81 | NOS1 (0.47) | NOS1SLC7A5CYP3A4 | |
| SCHEMBL20041146 | 0.81 | NOS1 (0.47) | NOS1SLC7A5CYP3A4 | |
| SCHEMBL31688766 | 0.81 | SLC7A5 (0.65) | NOS1SLC7A5KDM4E | |
| SCHEMBL18402873 | 0.80 | SLC7A5 (0.39) | NOS1SLC7A5TSHR | |
| SCHEMBL24899382 | 0.79 | MAOB (0.45) | MAPTMEN1KMT2A | |
| SCHEMBL9631293 | 0.79 | MAOB (0.45) | MAPTMEN1KMT2A | |
| SCHEMBL17211514 | 0.79 | GRIA2 (0.50) | CYP3A4KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11306125-B2 | PCSK9 antagonists bicyclo-compounds | MERCK SHARP & DOHME CORP. (US) | 2022-04-19 | — | — | US | disclosed |
| US-20210214395-A1 | PCSK9 ANTAGONISTS BICYCLO-COMPOUNDS | MERCK SHARP & DOHME LLC | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214395-A1 | PCSK9 ANTAGONISTS BICYCLO-COMPOUNDS | PCSK9, PCSK7, PCSK6 | NOS1 2468/4885SLC7A5 1980/4885PRMT6 1472/4885 |
| US-11306125-B2 | PCSK9 antagonists bicyclo-compounds | PCSK9, PCSK7, PCSK6 | NOS1 2468/4885SLC7A5 1980/4885PRMT6 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.